Psodisk, a new visual method for assessing the burden of psoriasis on patients

Linder, Dennis; Sampogna, Francesca; Torreggiani, Aldo; Balato, Nicola; Bianchi, Luca; Cassano, Nicoletta; Conti, Andrea; Gisondi, Paolo; Musumeci, Maria; Piaserico, Stefano; Potenza, Concetta; Romano, G.V.; Paparatti, Umberto di Luzio

doi:10.1111/j.1468-3083.2011.04192.x

Cited by 31 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An additional advantage of PSOdisk is how it is meant to be used during the clinical interview by the patient and the clinician together. This feature strengthens the value of answers (Linder, ). PSOdisk cut‐off scores have been recently determined to indicate psoriasis QoL disruption: (1) minimal (<9); (2) mild (9–15); (3) moderate (16–30); (4) marked (31–50); (5) severe (>50).…”

Section: Methodssupporting

confidence: 69%

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

Pistone

Gurreri

Tilotta

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with (r): .62. In terms of clinical scores improvement after 30 days, Ustekinumab turned out to be the fastest therapy available, while cyclosporine, among the systemic therapies available, appeared as highly competitive if not better than other biologic therapies.

show abstract

Section: Methodssupporting

confidence: 69%

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

Pistone

Gurreri

Tilotta

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The major limitations of the NHWS are the self‐reported data, which are based on patient recall of diagnoses and self‐reporting of outcomes which cannot be confirmed. One of the influencing factors which affect QoL is patient–physician relationship in both CU and PsO patients, and this has not been accounted for in this study 36, 37, 38. Another limitation might be that medical resource use was not collected for each individual comorbidity, but for the general health of the respondent.…”

Section: Discussionmentioning

confidence: 99%

Burden of chronic urticaria relative to psoriasis in five European countries

Balp

Khalil

Tian

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundQuantification of burden of chronic spontaneous urticaria (CSU) vs. psoriasis (PsO) is limited.ObjectiveTo evaluate the burden associated with CSU vs. PsO of all severities (overall PsO), mild and moderate/severe PsO.MethodsThis retrospective cross‐sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom. Outcomes included mental and physical component summary scores (MCS and PCS) calculated from the Short Form (SF)‐36v2 or SF‐12v2, SF‐6D health utility scores, self‐reported psychological complaints (anxiety, depression and sleep difficulties), work productivity and activity impairment, and self‐reported healthcare resource utilization. Bivariate and multivariate analyses for each outcome and comparative groups were conducted.ResultsThis analysis included 769 CU and 7857 PsO (26.9% moderate/severe) patients. Following adjustment for covariates, CU patients showed a greater health‐related quality of life (HRQoL) impairment vs. overall PsO (MCS: −2.4, PCS: −1.6, SF‐6D: −0.03; all P < 0.001). CU patients showed a higher risk of anxiety, depression and sleep difficulties [odds ratio (OR): 1.63, 1.34 and 1.56, respectively; all P < 0.01] and greater healthcare resource use vs. overall PsO. The overall activity impairment was significantly greater in CU patients than in overall PsO patients (P = 0.001), while the impact on work was not significantly different. The results vs. moderate/severe PsO group showed no significant differences on all outcomes.ConclusionBurden of illness in CU is higher than PsO of all severities but similar to that observed in moderate/severe PsO. Both diseases have a similar negative impact on work productivity.

show abstract

“…in the last decades, interesting data have been reported on the role of vitamin D on psoriasis, a Th1-Th17 immuno-mediated inflammatory disease (2,(9)(10)(11)(12)(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

The Potential Effect of the Tumour Necrosis Factor-α Inhibitors on Vitamin D Status in Psoriatic Patients

Ganzetti

Campanati²,

Scocco³

et al. 2014

Acta Derm Venerol

View full text Add to dashboard Cite

Psodisk, a new visual method for assessing the burden of psoriasis on patients

Abstract: A formal validation of the questionnaire and a study to assess potential clinical and psychological benefits of a systematic implementation of the instrument in daily practice are planned.

Cited by 31 publications

References 15 publications

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

Burden of chronic urticaria relative to psoriasis in five European countries

The Potential Effect of the Tumour Necrosis Factor-α Inhibitors on Vitamin D Status in Psoriatic Patients

Contact Info

Product

Resources

About